Results: The study patients (n=603) were predominantly male and had a mean ±SD age of 51.9 ±11.3 years, a gout duration of 11.8 ±9.4 years, a baseline serum UA level of 6.94 ±1.27 mg/dL, and were receiving an allopurinol dosage of 306.6 ±59.58 mg/day. Lesinurad at doses of 200 mg or 400 mg added to allopurinol therapy significantly increased the proportions of patients who achieved serum UA target levels by month 6 compared with those receiving allopurinol alone (54.2%, 59.2% and 27.9%, respectively, P<0.0001). Lesinurad was not significantly superior to allopurinol alone in terms of the secondary end points: rates of gout flares and complete resolution of tophi. Lesinurad was generally well tolerated; the safety profile of the 200 mg dose was comparable to that of allopurinol alone, except for higher incidences of predominantly reversible elevations of serum creatinine levels.
Conclusion: Lesinurad added to allopurinol represents a new treatment option for patients needing additional urate-lowering therapy.
Excerpted and adapted from:
Saag KG, Fitz-Patrick D, Kopicko P, et al. Lesinurad combined with allopurinol: A randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-Based Study). Arthritis Rheumatol. 2017 Jan;69(1):203–212. doi: 10.1002/art.39840.
